ry questions that drive clinical development to tactical sales planning for mature brands.
EXPERTISE | IMS Karin Berger, MBA • Karin Berger is Senior Scientific Consultant to IMS and previously Principal, Health Economics & Outcomes Research, at IMS in Germany with a particular focus on outcomes research, patientreported outcomes, and cost-effectiveness evaluation analyses at a national and international level. • Formerly Managing Director of MERG (Medical Economics Research Group), an independent German organization providing health economics services to the pharmaceutical industry, university hospitals and European Commission, Karin has more than 14 years experience in the health economics arena. She lectures at several universities, has published extensively in peer-reviewed journals, and regularly presents at economic and medical conferences around the world. • Karin graduated as Diplom-Kaufmann (German MBA equivalent) from the Bayreuth University, Germany, with a special focus on health economics. Christopher M. Blanchette, PHD, MS, MA • Dr. Chris Blanchette is Principal, Health Economics & Outcomes Research at the IMS Consulting Group in the U.S., bringing extensive experience in retrospective database research and observational studies with particular emphasis on respiratory diseases. • Chris was previously Director of Clinical & Outcomes Research at the Lovelace Respiratory Research Institute, where he led a team of 50 people conducting clinical research, biostatistics, and outcomes research programs. He also spent time in market access and R&D health economics at GlaxoSmithKline, most recently as Director for Health Data Analytics, and was formerly a researcher at the Premier Hospital Alliance and Agency for Healthcare Research and Quality. • In addition to serving in leadership positions for ISPOR and several respiratory disease associations, Christopher is on the editorial board of the Journal of Medical Economics and advisory board of Current Medical Research and Opinion. He holds a PhD in Pharmaceutical Health Services Research and an MS in Epidemiology from the University of Maryland, and an MA in Medical Sociology from the University of North Carolina. Nevzeta Bosnic, BA • Nevzeta Bosnic is Principal at IMS Brogan in Canada, where she manages projects to meet the broad spectrum of client needs in the Canadian pharmaceutical market. • Formerly Director of Economic Consulting at Brogan Inc, Nev has led many strategic consulting, policy and data analyses for pharmaceutical clients, government bodies and academic institutions in Canada. She has extensive knowledge of public and private drug plans across the country and in-depth expertise and experience on the drug reimbursement process. • Nev holds a Bachelor’s degree in Business Economics from the School of Economics and Business at the University of Sarajevo, Bosnia-Herzegovina. Joe Caputo, BSC • Joe Caputo is Principal, Health Economics & Outcomes Research at the IMS Consulting Group in the U.K., leveraging more than 15 years experience in the pharmaceutical sector to help clients address the challenges of global reimbursement and market access throughout the drug development program. He has led numerous projects involving payer research, value dossiers, local market access models and HTA submissions. • With a background that spans industry roles in drug development, sales & marketing and UK & global health outcomes, and consulting in health economics, Joe has wide-ranging knowledge of the drug development process at both local and international level and a unique understanding of evidence gaps in light of reimbursement and market access requirements. • Joe holds a BSc in Applied Statistics and Operational Research from Sheffield Hallam University, UK. Richard H. Chapman, PHD • Dr. Rick Chapman is Principal, Health Economics & Outcomes Research at the IMS Consulting Group in the U.S., directing the design and analysis of economic evaluations and health outcomes studies addressing a range of client issues. • Formerly a Senior Director at ValueMedics Research, and Research Associate at the Center for Risk Analysis, Rick has considerable experience in designing and conducting cost-effectiveness analyses, and particular expertise in the methodological quality of health economic analyses, medication adherence and patient-reported outcomes, including quality of life and patient preferences. • Rick holds a PhD in Health Policy (Decision Sciences) from Harvard University and an MS in Health Policy and Management from the Harvard School of Public Health.
AccessPoint - Issue 3
Page 55